Application of an algorithm to analyse patterns of intermittent oral corticosteroid use in asthma

John Haughney; Trung N Tran; Heath  Heatley; Arnaud Bourdin; Andrew Menzies-Gow; David J Jackson; Ekaterina  Maslova; Jatin  Chapaneri; Derek Skinner; Victoria Carter; Jeffrey  Shi Kai Chan; David Price

doi:10.1038/s41533-023-00331-0

Application of an algorithm to analyse patterns of intermittent oral corticosteroid use in asthma

John Haughney, Trung N Tran, Heath Heatley, Arnaud Bourdin, Andrew Menzies-Gow, David J Jackson, Ekaterina Maslova, Jatin Chapaneri, Derek Skinner, Victoria Carter, Jeffrey Shi Kai Chan, David Price^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

An algorithm to describe patterns of intermittent oral corticosteroid use in the UK (n=476,167) found that one-third of patients receiving intermittent oral corticosteroids for asthma only had short gaps (frequency pattern was more likely in patients with greater asthma severity and with more short acting β2-agonist use at baseline. Our approach may provide a clinically relevant representation of intermittent oral corticosteroid use in asthma.

Original language	English
Article number	9
Number of pages	5
Journal	npj Primary Care Respiratory Medicine
Volume	33
DOIs	https://doi.org/10.1038/s41533-023-00331-0
Publication status	Published - 4 Mar 2023

Bibliographical note

Acknowledgements
This project is based in part/wholly on data from the Optimum Patient Care Research Database (opcrd.co.uk) obtained under licence from Optimum Patient Care Limited and its execution is approved by recognised experts affiliated to the Respiratory Effectiveness Group. However, the interpretation and conclusion contained in this manuscript are those of the authors alone.
AstraZeneca funded the study and had a role in study design and data interpretation. The Observational & Pragmatic Research Institute had a role in study design and delivered the study protocol, data analysis, data interpretation and study report. The Observational & Pragmatic Research Institute received no funding for manuscript writing. The corresponding author had full access to all the data and had final responsibility to submit for publication.
We would like to thank Sam Hijazi and Stefan Courtney for providing medical writing support, which was funded by AstraZeneca in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

Data Availability Statement

The dataset supporting the conclusions of this article was derived from the Optimum Patient Care Research Database (www.opcrd.co.uk). The OPCRD has ethical approval from the National Health Service (NHS) Research Authority to hold and process anonymised research data (Research Ethics Committee reference: 15/EM/0150). This study was approved by the Anonymised Data Ethics Protocols and Transparency (ADEPT) committee – the independent scientific advisory committee for the OPCRD. The authors do not have permission to give public access to the study dataset; researchers may request access to OPCRD data for their own purposes. Access to OCPRD can be made via the OCPRD website (https://opcrd.co.uk/our-database/data-requests/) or via the enquiries email info@opcrd.co.uk. The dataset supporting the conclusions of this article was derived from the Optimum Patient Care Research Database. We do not have permission to give public access to this database, however, researchers may request access for their own purposes, in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access to Document

10.1038/s41533-023-00331-0Licence: CC BY

Haughney_etal_NPJPCRM_Application_Of_An_VOR
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Final published version, 671 KBLicence: CC BY

Cite this

@article{9178c84bca574ec0937b3328adb9a74a,

title = "Application of an algorithm to analyse patterns of intermittent oral corticosteroid use in asthma",

abstract = "An algorithm to describe patterns of intermittent oral corticosteroid use in the UK (n=476,167) found that one-third of patients receiving intermittent oral corticosteroids for asthma only had short gaps (frequency pattern was more likely in patients with greater asthma severity and with more short acting β2-agonist use at baseline. Our approach may provide a clinically relevant representation of intermittent oral corticosteroid use in asthma.",

author = "John Haughney and Tran, {Trung N} and Heath Heatley and Arnaud Bourdin and Andrew Menzies-Gow and Jackson, {David J} and Ekaterina Maslova and Jatin Chapaneri and Derek Skinner and Victoria Carter and {Shi Kai Chan}, Jeffrey and David Price",

note = "Acknowledgements This project is based in part/wholly on data from the Optimum Patient Care Research Database (opcrd.co.uk) obtained under licence from Optimum Patient Care Limited and its execution is approved by recognised experts affiliated to the Respiratory Effectiveness Group. However, the interpretation and conclusion contained in this manuscript are those of the authors alone. AstraZeneca funded the study and had a role in study design and data interpretation. The Observational & Pragmatic Research Institute had a role in study design and delivered the study protocol, data analysis, data interpretation and study report. The Observational & Pragmatic Research Institute received no funding for manuscript writing. The corresponding author had full access to all the data and had final responsibility to submit for publication. We would like to thank Sam Hijazi and Stefan Courtney for providing medical writing support, which was funded by AstraZeneca in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).",

year = "2023",

month = mar,

day = "4",

doi = "10.1038/s41533-023-00331-0",

language = "English",

volume = "33",

journal = "npj Primary Care Respiratory Medicine",

issn = "2055-1010",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Application of an algorithm to analyse patterns of intermittent oral corticosteroid use in asthma

AU - Haughney, John

AU - Tran, Trung N

AU - Heatley, Heath

AU - Bourdin, Arnaud

AU - Menzies-Gow, Andrew

AU - Jackson, David J

AU - Maslova, Ekaterina

AU - Chapaneri, Jatin

AU - Skinner, Derek

AU - Carter, Victoria

AU - Shi Kai Chan, Jeffrey

AU - Price, David

N1 - Acknowledgements This project is based in part/wholly on data from the Optimum Patient Care Research Database (opcrd.co.uk) obtained under licence from Optimum Patient Care Limited and its execution is approved by recognised experts affiliated to the Respiratory Effectiveness Group. However, the interpretation and conclusion contained in this manuscript are those of the authors alone. AstraZeneca funded the study and had a role in study design and data interpretation. The Observational & Pragmatic Research Institute had a role in study design and delivered the study protocol, data analysis, data interpretation and study report. The Observational & Pragmatic Research Institute received no funding for manuscript writing. The corresponding author had full access to all the data and had final responsibility to submit for publication. We would like to thank Sam Hijazi and Stefan Courtney for providing medical writing support, which was funded by AstraZeneca in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

PY - 2023/3/4

Y1 - 2023/3/4

N2 - An algorithm to describe patterns of intermittent oral corticosteroid use in the UK (n=476,167) found that one-third of patients receiving intermittent oral corticosteroids for asthma only had short gaps (frequency pattern was more likely in patients with greater asthma severity and with more short acting β2-agonist use at baseline. Our approach may provide a clinically relevant representation of intermittent oral corticosteroid use in asthma.

AB - An algorithm to describe patterns of intermittent oral corticosteroid use in the UK (n=476,167) found that one-third of patients receiving intermittent oral corticosteroids for asthma only had short gaps (frequency pattern was more likely in patients with greater asthma severity and with more short acting β2-agonist use at baseline. Our approach may provide a clinically relevant representation of intermittent oral corticosteroid use in asthma.

U2 - 10.1038/s41533-023-00331-0

DO - 10.1038/s41533-023-00331-0

M3 - Article

SN - 2055-1010

VL - 33

JO - npj Primary Care Respiratory Medicine

JF - npj Primary Care Respiratory Medicine

M1 - 9

ER -

Application of an algorithm to analyse patterns of intermittent oral corticosteroid use in asthma

Abstract

Bibliographical note

Data Availability Statement

Access to Document

Fingerprint

Cite this